Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) developer of the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease that leads to cancer, today announced that it will be a featured presenter at the 3rd Annual Marcum MicroCap...
The LuViva® Advanced Cervical Scan identified 100% of all cervical disease cases in a blinded clinical study presented at the International Federation for Cervical Pathology and Colposcopy (IFCPC) meeting in London on May 27, 2014. LuViva also correctly identified 44%...
Guided Therapeutics, Inc. (OTCQB: GTHP) today announced that it has issued and sold to Magna Group affiliate Hanover Holdings I, LLC the final $2,000,000 in principal amount of senior convertible notes under the terms of the previously disclosed Securities Purchase...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced its operating results for the first quarter ended March 31, 2014. Revenue and other income for the first quarter ended March 31, 2014 was approximately $141,000, including approximately $122,000 in...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that as a result of its “productive” discussion with officials of the U.S. Food and Drug Administration (FDA) last week, the Company plans to submit an amendment to its premarket approval (PMA)...
